The Analysis of Heart Rate Variability With 24hrs Holter ECG and Serum Cardiac Fibrosis Markers in Critical Illness Patients Who Are With Cardiogenic Shock, With ECMO or IABP Support, or With APACH II Score >25)

Completed

• Conditions: With ECMO or IABP Support,; With APACH II Score >25); Cardiogenic Shock,

• Registration Number: NCT01993745
• Lead Sponsor: National Taiwan University Hospital

Brief Summary

The study is to show the prognostic factor of HRV parameter and cardiac fibrosis markers in critical illness patients

Detailed Description

The analysis of Heart Rate Variability with 24hrs Holter ECG and serum cardiac fibrosis markers in critical illness patients who are with cardiogenic shock, with ECMO or IABP support, or with APACH II score \>25)

Study Timeline

• Study Start: 2008-05
• Primary Completion: 2009-05
• Study Completion: 2009-12
• Study First Submitted: 2013-10-29
• Status Verified: 2013-11
• Study First Submitted QC: 2013-11-20
• Last Update Submitted: 2013-11-20
• Study First Posted: 2013-11-25
• Last Update Posted: 2013-11-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 106

Inclusion Criteria

• critical illness patients who are with cardiogenic shock, with ECMO or IABP support, or with APACH II score >25)

Exclusion Criteria

• pacemaker rhythm, not sign the permit

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Heart Rate Variability and serum cardiac fibrosis markers in critical illness patients	2-4weeks	1. Outcome measurement: The measure is a composite outcome measure consisting of multiple measures (results to be reported as a single value for each Arm/Group), no changes are required; 2. List the primary condition or disease being studied Shock needing ECMO support

Trial Locations

Locations (1)

National Taiwan University Hospital; 🇨🇳 Taipei, Taiwan